Navigation Links
Vermillion Reports Second Quarter 2014 Results
Date:8/14/2014

c approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995 that involve significant risks and uncertainties including statements regarding Vermillion's future revenue, Vermillion's expected cash outlay and future test volumes. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ from those projected in such forward-looking statements include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products or otherwise comply with applicable laws and regulations; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, the ... the formation of the DripDrop Foundation, with its ... dehydration worldwide. Utilizing scientific advancements in Oral Rehydration ... to reduce dehydration and healthcare costs through strategic ... "DripDrop has been used in ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... new additions to its Scientific Advisory Board.  The new ... Anthony Davies , PhD. Dr. Acker is ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... Adeona Pharmaceuticals, Inc. (AMEX: ... for serious central nervous system diseases, announced today ... the randomized, double-blind, placebo-controlled, multi-center clinical trial of ... multiple sclerosis (MS) in women, per the original ...
... MARLBOROUGH, Mass., Sept. 19, 2011 Advanced Cell Technology, ... of regenerative medicine, announced today that it has been ... the Company,s proprietary method for generating and expanding hemangioblast ... an exclusive license to commercialize the patented technology in ...
Cached Medicine Technology:Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 2Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 3Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 4Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial 5ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 2ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 3ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders 4
(Date:9/23/2014)... California (PRWEB) September 23, 2014 ... transcription is the process of translating the entire ... course, therapeutic procedures, and prognosis, into a readable ... agents, patients, and healthcare providers. With attending physicians ... each patient’s condition, outsourcing of such documentation to ...
(Date:9/23/2014)... go to Mars, will astronauts be able to grow ... they be able to produce food in NASA,s Orion ... growing food on Earth under extreme conditions? These are ... growth in microgravity on the International Space Station (ISS). ... fundamental genetic mechanisms plants use to adapt to a ...
(Date:9/23/2014)... NJ (PRWEB) September 23, 2014 Visiting ... provider of home health care, hospice and palliative care, ... to ring the Opening Bell last week at the ... a New Jersey philanthropist and social entrepreneur to care ... VNA Health Group has always worked to meet the ...
(Date:9/23/2014)... Becker's Hospital Review has published the 2014 edition ... Systems With Great Orthopedic Programs." , The hospitals ... orthopedic surgery departments, programs or dedicated centers that ... orthopedic departments include physicians who provide outstanding care ... athletes. , This is the fifth year Becker's ...
(Date:9/23/2014)... better screening strategies can lower the rate of false-positive ... on women. The many misperceptions about breast cancer screening ... and the need for new approaches and better education ... supplement to Journal of Women,s Health , a ... supplement is available free on the Journal of ...
Breaking Medicine News(10 mins):Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 2Health News:Expanding Healthcare Sector Drives Demand for Medical Transcription Services, According to New Report by Global Industry Analysts, Inc. 3Health News:Getting to the root of the problem in space 2Health News:Getting to the root of the problem in space 3Health News:Getting to the root of the problem in space 4Health News:NJ's Largest Nonprofit Home Health Care Agency Joins Deutsche Bank to Ring New York Stock Exchange Opening Bell 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:Opportunities to reduce patient burden associated with breast cancer screening 2
... in Attack and Stalking at Homes, OAKLAND, Calif., ... on a labor conference in Michigan Saturday night by ... Nurses Organizing Committee Monday called on SEIU,President Andrew Stern ... nurses, and working people for threats and harassment.", ...
... to,the State of Iowa,s new smoke-free law, the American ... Tobacco-Free" conference on April,29th in Coralville, Iowa to assist ... will offer information on the new law,and feature speakers ... businesses that have questions about the law and the ...
... identified in the blood of chronic sinusitis sufferers that ... disease, researchers say. , They used a sophisticated research ... proteins and found among 96 chronic sinusitis patients a ... can diagnose this disease with a totally objective test ...
... month, two,men from Massachusetts will begin The Elias Tembenis ... autism awareness and funds to,assist children with the diagnosis., ... walk approximately,3000 miles in honor of Elias Tembenis, a ... a seizure. Tembenis family friends,Williams and Genese hope to ...
... 14 A board-certified,radiologist, Fred Steinberg, M.D., his ... Fla., have reached a settlement with the United,States ... Justice Department,announced today. Under the terms of the ... resolves allegations that portions of CT scans were ...
... Region 5 has reached an agreement with American ... coal preparation,plant at 43521 Mayhugh Hill Road, Township ... includes a $40,000 penalty, resolves EPA,allegations that AEC ... at the plant that processes coal from a ...
Cached Medicine News:Health News:RNs Call on Service Employees Union (SEIU) President Stern to Renounce Violence Following Brutal Attack on Labor Event 2Health News:RNs Call on Service Employees Union (SEIU) President Stern to Renounce Violence Following Brutal Attack on Labor Event 3Health News:Potential blood test for chronic sinusitis identified 2Health News:Two Men to Walk Across America for Autism Aid, Awareness, and Loving Memory of Young Boy 2Health News:Florida Radiologist to Pay U.S. $7 Million to Resolve Fraud Claims 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
Medicine Products: